Fulvic Acid for Cognitive Function

Research suggests that fulvic acid shows early preclinical promise for cognitive health, particularly in the context of Alzheimer's disease pathology, with laboratory studies consistently reporting that it can inhibit the formation of tau protein tangles and amyloid-beta aggregates, reduce protein clumping associated with both Alzheimer's and Parkinson's disease, and demonstrate neuroprotective effects against oxidative stress and heavy metal toxicity in animal models. The available evidence base consists predominantly of in vitro and in silico studies, a small number of animal experiments, and one narrative review that included a limited clinical trial component examining shilajit — a natural substance rich in fulvic acid — in patients with mild Alzheimer's disease, with all findings pointing in a supportive direction though none constituting robust clinical proof. Studies indicate that fulvic acid has also been explored in combination formulations alongside compounds like Bacopa monnieri, where animal behavioral studies suggested improvements in memory performance, though it is difficult to isolate fulvic acid's specific contribution in multi-ingredient preparations. The overall body of evidence remains at an early, largely preclinical stage, with no large-scale randomized controlled trials establishing efficacy or safety in humans, meaning conclusions about meaningful cognitive benefit cannot yet be drawn from the existing literature.